Weiner David B.'s Form 4 filing
Inovio Pharmaceuticals, Inc. (INO) · filed Aug 11, 2022
- Accession no.
- 0001055726-22-000050
- Filed
- Aug 11, 2022
- Trade date
- Aug 11, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $31.6K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weiner David B.CIK 0001669080 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2022 | Common Stock | MOption exerciseAcquired | +11,875 | $2.16 | +$25,650 | 904,500 | Direct | |
| Aug 11, 2022 | Common Stock | SSaleDisposed | −11,875 | $2.66F2 | −$31,587.5 | 892,625 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2022 | Common Stock | MOption exerciseDisposed | −11,875 | $0.00 | $0 | 11,875 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
These transactions were executed in multiple trades at prices ranging from $2.66 to $2.69, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.